Search results for "asthma"

showing 10 items of 860 documents

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

2021

International audience; Severe asthma often remains uncontrolled despite effective treatments and evidence-based guidelines. A group of global experts in asthma and biologic medications from nine countries considered the most relevant clinical variables to manage severe asthma in adult patients and guide treatment choice. The resulting recommendations address the investigation of biomarker levels (blood eosinophil count along with fractional concentration of exhaled nitric oxide [FeNO]), clinical features (oral corticosteroid [OCS] dependency, specific comorbid disease entities associated with severe type 2 asthma), and safety considerations. Current evidence suggests that biomarkers, inclu…

Adultsevere asthmamedicine.medical_specialty[SDV]Life Sciences [q-bio]Nitric Oxide[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Health caremedicineImmunology and AllergyHumans[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyIntensive care medicineExpert TestimonyAsthmaBiological Productsalgorithmbusiness.industrymedicine.diseaseAsthma3. Good healthClinical trialClinical research030228 respiratory systemExhalation030220 oncology & carcinogenesisExhaled nitric oxide[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractBiomarker (medicine)Sputumeosinophilsmedicine.symptombusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
researchProduct

Asthma in the elderly: mortality rate and associated risk factors for mortality.

2007

BACKGROUND: There is a distinct lack of information on the prognosis of asthma in the elderly. METHODS: In order to compare mortality rates of elderly people with and without asthma and to identify mortality risk factors in those with asthma, 1,233 ambulatory patients aged > or = 65 years with a diagnosis of asthma (n = 210) or chronic nonrespiratory conditions (n = 1,023) were enrolled in a multicentric study. Patients underwent baseline spirometry and multidimensional assessment and were then followed up for a mean of 57.9 months (SD 16.9). We compared mortality rates in the two groups and identified predictors of death using multivariable survival analysis. RESULTS: The 5-year mortality …

Aged 80 and overMaleDepressionRisk FactorsForced Expiratory VolumeHumansFemaleComorbidityGeriatric AssessmentSurvival AnalysisAsthmaAgedBody Mass IndexChest
researchProduct

Effects of chronic airway disease on health status of geriatric patients.

2004

Background and aims: The impact of chronic airway disease on the health status of elderly patients is only to some extent explained by indexes of airflow limitation. The present study was designed to assess to what extent: 1) asthma, chronic obstructive pulmonary disease (COPD) and chronic bronchitis with normal FEV1 (simple bronchitis) differ in their impact on health status; 2) health status depends upon non-respiratory factors. Methods: A total of 1601 outpatients over 65 - 198 with asthma, 228 with COPD, 91 with simple bronchitis, and 1084 with non-respiratory illnesses (control group) -were studied by collection of five health status indexes and multidimensional assessment. Discriminan…

AgingChronic bronchitismedicine.medical_specialtyHealth StatusSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveInternal medicinemedicineHealth Status IndicatorsHumansRespiratory functionBronchitisAsthmaAgedCOPDbusiness.industryAnthropometrymedicine.diseaseComorbidityAsthmarespiratory tract diseasesAirway diseaseChronic DiseasePhysical therapyBronchitisaging quality of life COPDGeriatrics and GerontologybusinessAlgorithmsAging clinical and experimental research
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Diagnosis and management of asthma in the elderly.

2013

Bronchial asthma is one of the most common chronic diseases worldwide, and by definition not expected to recover with aging. However, the concept that asthma can affect older individuals has been largely denied in the past. In clinical practice, asthma that occurs in the most advanced ages is often diagnosed as COPD, thus leading to undertreatment or improper treatment. The heterogeneity of clinical and functional presentation of geriatric asthma, including the partial loss of reversibility and of the allergic component, contributes to this misconception. A large body of evidence has accumulated demonstrating that the prevalence of asthma in the most advanced ages is similar to that in youn…

Agingmedicine.medical_specialtyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Human lungMedication AdherenceOlder patientsPartial lossInternal MedicinemedicineHumansAnti-Asthmatic AgentsIntensive care medicineAsthmaAgedCOPDbusiness.industryAsthma treatmentAge Factorsmedicine.diseaseComorbidityLung functionAsthmarespiratory tract diseasesClinical Practicemedicine.anatomical_structurePhysical therapybusinessAirway inflammationEuropean journal of internal medicine
researchProduct

Challenges in the pharmacological treatment of geriatric asthma

2016

ABSTRACTAsthma in older populations is characterized by frequent comorbid conditions, which increase the risk of side effects and of detrimental interactions between respiratory and non-respiratory drugs. These observations lead to the need to manage asthma in older populations by applying a multidimensional assessment and a multidisciplinary treatment; therefore, we favor the use of the ‘geriatric’ term to define asthma in the elderly. Geriatric asthma is a complex disease, which may not necessarily imply that it is also complicated, although the two conditions may often coexist. On this basis, the switch from an organ-driven management to the holistic approach may be the key factor to att…

Agingmedicine.medical_specialtyComplex diseaseComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentPharmacological treatmentOlder population03 medical and health sciences0302 clinical medicineMultidisciplinary approachAnimalsHumansMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicinePsychiatryAgedAsthmabusiness.industryAge FactorsGeneral Medicinemedicine.diseaseComorbidityAsthmaInhaled treatment030228 respiratory systemAdherencePharmacology Toxicology and Pharmaceutics (all)businessExpert Review of Clinical Pharmacology
researchProduct

Comorbidities of Lung Disease in the Elderly

2017

Comorbidities are common in elderly individuals with chronic respiratory diseases. They can affect disease manifestations and severity and can even impact management. Comorbidities can affect the treatment of the lung disease, particularly because of the interaction with the respiratory drugs. Thus, a multidimensional approach with multidisciplinary intervention is suggested for elderly respiratory patients, switching from a disease-oriented scheme to a dysfunction-oriented approach. Unfortunately, older individuals are often excluded from clinical trials because of advanced age and comorbidities. This article reviews the role of comorbidities in the management of respiratory diseases in th…

Agingmedicine.medical_specialtyRespiratory Tract DiseasesComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineHumansSenile lung030212 general & internal medicineRespiratory systemIdiopathic lung fibrosiIntensive care medicineRespiratory Tract DiseaseAgedAsthmabusiness.industryChronic obstructive pulmonary diseasefood and beveragesmedicine.diseaseComorbidityAsthmaPatient Care ManagementClinical trial030228 respiratory systemLung diseaseGeriatrics and GerontologybusinessHumanClinics in Geriatric Medicine
researchProduct

Mild to moderate chronic airways disease does not carry an excess risk of cognitive dysfunction

2003

Whether chronic obstructive pulmonary disease (COPD) carries a risk of cognitive dysfunction prior to the onset of arterial hypoxemia is not known. Our objective was to assess both the prevalence and main correlates of subclinical cognitive dysfunction in older patients with non-hypoxemic COPD.Home-dwelling non-demented subjects over 64 years of age consecutively attending 24 outpatient Departments of Respiratory Medicine or Geriatrics because of COPD (N = 233), asthma (N = 203), non-obstructive bronchitis (N = 92) or chronic non-respiratory and non-dementing diseases (controls, N = 1080) underwent a multidimensional assessment. Cognitive status was assessed by the Mini-Mental State Examina…

Agingmedicine.medical_specialtyVital capacityNeuropsychological TestsSeverity of Illness IndexPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineSeverity of illnessmedicineHumansRespiratory functionAgedAsthmaAged 80 and overGeriatricsCOPDbusiness.industrymedicine.diseaseMultivariate AnalysisPhysical therapyBronchitisGeriatric Depression ScaleGeriatrics and GerontologyCognition DisordersbusinessAging Clinical and Experimental Research
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct